Clinical Trials on Intraocular Melanoma

Total 3566 results

Vastra Gotaland Region

Not yet recruiting

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases (HAITILS-PHP)

Metastatic Cutaneous Melanoma | Uveal Melanoma
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IV | BRAF V600 Mutation | Melanoma Stage III

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Recurrent Melanoma | Stage IV Melanoma

United States
Oslo University Hospital

Completed

Liver Transplantation and Uveal Malignant Melanoma

Uveal Malignant Melanoma

Norway
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Center

Completed

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Bristol-Myers Squibb

Completed

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Unresectable Stage III or IV Malignant Melanoma

United States, Peru, Norway, Italy, Sweden, Denmark, Israel
National Cancer Institute (NCI)

Terminated

A Phase II Study of UCN-01 in Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

BMS-247550 in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Viral Therapy in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Leeds Cancer Centre at St. James's University Hospital

Unknown

Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

Melanoma (Skin) | Hereditary Multiple Melanoma

United Kingdom
National Cancer Institute (NCI)

Completed

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute, Naples

Completed

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma (SICOG 0109)

Recurrent Melanoma | Malignant Melanoma
Bart Neyns
Vrije Universiteit Brussel

Completed

Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

Belgium
Baylor Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

United States
California Cancer Assocaties for Research & Excellence

Unknown

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Metastatic Melanoma | Malignant Melanoma of Skin Stage III

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); University of Virginia

Completed

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin Melanoma

United States
Johns Hopkins University
King Khaled Eye Specialist Hospital

Completed

An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children

Intraocular Pressure | Anesthesia

Saudi Arabia
Vastra Gotaland Region

Withdrawn

Surgery of Melanoma Metastases After Systemic Therapy (SUMMIST)

Melanoma | Surgery | Metastatic Melanoma | Melanoma Stage IV

Sweden
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Acral Melanoma That Has Been Removed by Surgery

China
National Cancer Institute (NCI)

Completed

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Haukeland University Hospital
Norwegian Cancer Society; The Norwegian Melanoma Group

Terminated

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Metastatic Malignant Melanoma | Unresectable Malignant Melanoma

Norway
Herlev Hospital

Completed

Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

Malignant Melanoma With Metastasis

Denmark
Dermatologic Cooperative Oncology Group

Unknown

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Therapy | Adjuvant | Stage III Malignant Melanoma | Interferon Alpha

Germany
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Unresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Unresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous Melanoma

China
Eyebright Medical Technology (Beijing) Co., Ltd.

Completed

Clinical Validation Plan of Capsular Tension Ring (CVPOCTR)

Intraocular Lens Implantation
University of Washington
National Cancer Institute (NCI)

Terminated

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Eisai Inc.

Terminated

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Unresectable Stage III Melanoma | Wild Type BRAF Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Withdrawn

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Melanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
William Carson
Schering-Plough

Completed

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
Biocad

Recruiting

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (NEO-MIMAJOR)

Melanoma (Skin) | Melanoma Stage III

Russian Federation, Belarus
Mayo Clinic
National Cancer Institute (NCI)

Completed

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Biocad

Recruiting

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Advanced Melanoma

Russian Federation, Belarus

Clinical Trials on Intraocular Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations